CliffBio
small molecule

XOFIGO

RADIUM RA-223 DICHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameXOFIGO
Active ingredientRADIUM RA-223 DICHLORIDE
Strength162mCi/6ML (27mCi/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2013
Marketing statusRX

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.